<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>Phanes Therapeutics announces first biliary tract carcinoma (BTC) patient dosed in clinical study of spevatamig in combination with chemotherapy — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Phanes Therapeutics announces first biliary tract carcinoma (BTC) patient dosed in clinical study of spevatamig in combination with chemotherapy</h2>
    <div class="badge">2025-09-08T17:18:00+00:00</div>
    <ul>
      <li>8, 2025 /PRNewswire/ -- Phanes Therapeutics, Inc.</li>
<li>In 2023, Phanes entered into a clinical collaboration agreement with Merck (known as MSD outside the US and Canada) to study spevatamig in combination with Merck&#x27;s anti-PD-1 therapy, pembrolizumab.</li>
<li>It was granted orphan drug designation (ODD) for the treatment of pancreatic cancer by the FDA in 2022 and was granted Fast Track designation for the treatment of patients with metastatic claudin 18.2-positive pancreatic</li>
<li>Spevatamig is a first-in-class native IgG-like bispecific antibody (bsAb) targeting claudin 18.2 and CD47.</li>
<li>ABOUT PHANES THERAPEUTICS Phanes Therapeutics, Inc.</li>
<li>For more information about Phanes Therapeutics, please visit www.phanesthera.com.</li>
<li>View original content to download multimedia:https://www.prnewswire.com/news-releases/phanes-therapeutics-announces-first-biliary-tract-carcinoma-btc-patient-dosed-in-clinical-study-of-spevatamig-in-combination-with-chem</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=Phanes Therapeutics announces first biliary tract carcinoma (BTC) patient dosed in clinical study of spevatamig in combination with chemotherapy\n• 8, 2025 /PRNewswire/ -- Phanes Therapeutics, Inc.\n• In 2023, Phanes entered into a clinical collaboration agreement with Merck (known as MSD outside the US and Canada) to study spevatamig in combination with Merck&#x27;s anti-PD-1 therapy, pembrolizumab.\n• It was granted orphan drug designation (ODD) for the treatment of pancreatic cancer by the FDA in 2022 and was granted Fast Track designation for the treatment of patients with metastatic claudin 18.2-positive pancreatic\n• Spevatamig is a first-in-class native IgG-like bispecific antibody (bsAb) targeting claudin 18.2 and CD47.\n• ABOUT PHANES THERAPEUTICS Phanes Therapeutics, Inc.\n• For more information about Phanes Therapeutics, please visit www.phanesthera.com.\n• View original content to download multimedia:https://www.prnewswire.com/news-releases/phanes-therapeutics-announces-first-biliary-tract-carcinoma-btc-patient-dosed-in-clinical-study-of-spevatamig-in-combination-with-chem" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/news/phanes-therapeutics-announces-first-biliary-171800589.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>